Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients

Leukemia Research

Volumn 39, Issue 10, 2015, Pages 1055-1059

  Breccia, Massimo ^a   Efficace, Fabio ^b   Sica, Simona ^c   Abruzzese, Elisabetta ^d   Cedrone, Michele ^e   Turri, Diamante ^f   Gobbi, Marco ^g   Carella, Angelo Michele ^g   Gozzini, Antonella ^h   Usala, Emilio ⁱ   Cavazzini, Francesco ^j   Danise, Paolo ^k   Tiribelli, Mario ^l   Binotto, Gianni ^m   Pregno, Patrizia ^e   Bocchia, Monica ⁿ   Gaidano, Gianluca ^o   Crugnola, Monica ^p   Bonifacio, Massimiliano ^q   Avanzini, Paolo ^r   Celesti, Francesca ^s   Guella, Anna ^t   Martino, Bruno ^u   Annunziata, Mario ^v   Luciano, Luigiana ^w   Stagno, Fabio ^x   Vallisa, Daniele ^y   Pungolino, Esther ^z   Iurlo, Alessandra ^aa   Rambaldi, Alessandro ^ab   Nardiello, Ida ^ac   Orlandi, Esther ^ad   Gambacorti Passerini, Carlo ^ae   Alimena, Giuliana ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Data Center and Health Outcomes Research Unit   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d S EUGENIO HOSPITAL   (Italy)

^e MOLINETTE HOSPITAL   (Italy)

^f Department of Surgery   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ Businco Hopsital   (Italy)

^j UNIVERSITY OF FERRARA   (Italy)

^k ASL Salerno   (Italy)

^l UNIVERSITY OF UDINE   (Italy)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ UNIVERSITY OF SIENA   (Italy)

^o UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^p UNIVERSITY OF PARMA   (Italy)

^q UNIVERSITY OF VERONA   (Italy)

^r UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^s BELCOLLE HOSPITAL   (Italy)

^t Trento Hospital   (Italy)

^u BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^v CARDARELLI HOSPITAL   (Italy)

^w UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^x UNIVERSITY OF CATANIA   (Italy)

^y GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^z OSPEDALE NIGUARDA CA GRANDA   (Italy)

^aa FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^ab Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^ac UNIVERSITY OF BRESCIA   (Italy)

^ad FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ae UNIVERSITY OF MILANO BICOCCA   (Italy)

more..

Author keywords

Adherence; Chronic myeloid leukemia; Survey

Indexed keywords

PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE;

ADOLESCENT; ADULT; AGED; ANXIETY; ARTICLE; ATTITUDE TO HEALTH; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOCTOR PATIENT RELATION; DRUG EFFICACY; FAMILY LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMFORT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SOCIAL LIFE; SOCIAL PROBLEM; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84941317056     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.07.004     Document Type: Article

References (21)

1. Deininger M., Buchdunger E., Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105:2640-2653.
2. Hahn E.A., Glendenning G.A., Sorensen M.V., et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J. Clin. Oncol. 2003, 21:2138-2146.
3. Efficace F., Baccarani M., Breccia M., et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011, 118:4554-4560.
4. Noens L., van Lierde M.A., De Bock R., et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009, 113:5401-5411.
5. Marin D., Bazeos A., Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol. 2010, 28:2381-2388.
6. Eliasson L., Clifford S., Barber N., et al. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk. Res. 2011, 35:626-630.
7. Ruddy K., Mayer E., Partridge A. Patient adherence and persistence with oral anticancer treatment. CA: Cancer J. Clin. 2009, 59:56-66.
8. Partridge A.H., Avorn J., Wang P.S., et al. Adherence to therapy with oral antineoplastic agents. J. Natl. Cancer Inst. 2002, 94:652-661.
9. Breccia M., Efficace F., Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?. Leuk Res 2011, 300(2):115-121.
10. Efficace F., Baccarani M., Rosti G., et al. Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. Br. J. Cancer 2012, 107:904-909.
11. Sharf G., et al. Non-adherence in chronic myeloid leukemia: results of a global survey of 2546 CML patients in 79 countries. Haematologica 2013, 98(S1):453. (abs. 104; 18th Congress of the European Hematology Association (EHA), June, 2013, Stockholm, Sweden).
12. Efficace F., Rosti G., Cottone F., et al. Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leuk Res. 2014, 38:294-298.
13. Partridge A., Avorn J., Wang P.S., Winer E.P. Adherence to therapy with oral antineoplastic agents. J. Natl. Cancer Inst. 2002, 94:652-661.
14. Osterberg L., Blaschke T. Adherence to medication. N. Engl. J. Med. 2005, 353:487-497.
15. Greenberg R.N. Overview of patient compliance with medication dosing: a literature review. Clin. Ther. 1984, 6:592-599.
16. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
17. Ross D.M., Branford S., Seymour J.F., et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013, 122:515-522.
18. Takahashi N., Kyo T., Maeda Y., et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 2012, 97:903-906.
19. Yhim H.Y., Lee N.R., Song E.K., et al. Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk. Res. 2012, 36:689-693.
20. Mahon F.X., Rea D., Guilhot J., et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010, 11:1029-1035.
21. Mahon F.X., et al. Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study 2014, ASH.